Kintara Reports Topline Results From Phase 2 Clinical Trial of VAL-083 for Recurrent GBM July 1, 2021 • 8:00 AM EDT
Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors June 3, 2021 • 8:00 AM EDT
Kintara Therapeutics to Present at the LD Micro Virtual Invitational Conference on June 9, 2021 June 2, 2021 • 8:00 AM EDT
Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3 Clinical Trial for Glioblastoma May 26, 2021 • 8:00 AM EDT
Kintara Therapeutics Announces Fiscal Third Quarter 2021 Financial Results and Provides Corporate Update May 14, 2021 • 8:00 AM EDT
Kintara Therapeutics to Participate at the Benzinga Global Small Cap Conference May 5, 2021 • 8:00 AM EDT
Kintara Presents Updates on Two Phase 2 Clinical Trials at the 2021 American Association for Cancer Research Annual Meeting April 12, 2021 • 8:00 AM EDT
Kintara Therapeutics to Participate in Benzinga Biotech Small Cap Conference March 17, 2021 • 8:00 AM EDT